Engrail Therapeutics

Health Care · Prescription Drugs

Facts

as of Nov 17, 2026

Engrail delivers transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.

Official records
Wikidata Q140045660
Website
engrail.com
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Financials

Funding rounds, investors and revenue on record.

$189MTotal raised
Series BLatest round
3Rounds and grants
Money by yearUSD, rounds and grants
2024$157M1 record
2021-1 record
2020$32M1 record
Largest rounds and grants
$157M
$32M
Sources: funding announcements, grant and company registers

Milestones

Each milestone is dated by its source: registers, filings, the press

Newsroom

Sep 18, 20242024
Blog
The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in healthy volunteers SAN DIEGO, Sept.…
Aug 8, 20242024
News · YahooFinance
$10 Million Investment Received from Foresite Capital in Extension of Series B FinancingSAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Engrail Therapeutics, a precision neuroscienc…
Mar 19, 20242024
Press release
SAN DIEGO - March 19, 2024 - Engrail Therapeutics (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve th…
Aug 3, 20212021
Press release
SAN DIEGO-(BUSINESS WIRE)-Engrail Therapeutics (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric th…
Feb 2, 20212021
Press release
SAN DIEGO-(BUSINESS WIRE)-Engrail Therapeutics (Engrail) today announced that it has acquired NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation.…
Jul 29, 20202020
Press release
SAN DIEGO-(BUSINESS WIRE)-Engrail Therapeutics (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric th…
Sources: the outlets named on each headline, each story once